Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Britain Courts Anthropic Amid US Defense Department Dispute 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
ST. LOUIS, Jan. 27, 2017 -- GeneriCo, LLC (“GeneriCo”), a global generic specialty pharmaceutical company, is pleased to announce that George R. Stevenson has joined the Company’s Board of Directors as the new Chairman of the Board. Mr. Stevenson brings deep generic and brand pharmaceutical expertise to the GeneriCo Board and is a seasoned pharmaceutical executive with many years of leadership in this dynamic marketplace. Mr. Stevenson most recently served as the President and Chief Executive Officer of Kremers Urban Pharmaceuticals (Division of UCB, Inc.) which was acquired in 2015 by Lannett Company, Inc. for $1.23B.
At Kremers Urban, George Stevenson led the Company’s growth from minimal value in 2007 to $1.23 billion in 2015. As part of this growth, Mr. Stevenson oversaw the approval of 12 FDA approved products, with another 30 products added to the R&D portfolio. Prior to Kremers Urban, Mr. Stevenson was Vice President of Generic Business & Trade Affairs at Endo Pharmaceuticals, and prior to that was successful during his professional career at Sandoz Inc. (Division of Novartis AG), Apothecon (Division of BMS), United Research Laboratories and Sun Company.
Tom Brya, CEO GeneriCo, stated, “We are thrilled to add George Stevenson to our Board of Directors. He will bring a depth of generic pharmaceutical expertise and leadership to add to our Board. His guidance will be invaluable as our ANDA pipeline products progress to approval and launch.”
About GeneriCo
GeneriCo is a generic pharmaceutical company focused on developing and marketing niche, high barrier drugs in the U.S. utilizing its proprietary data-driven, algorithm-based product selection process. The Company employs a four-pillar collaboration business strategy capitalizing on management’s deep industry knowledge and experience to collaborate with partners on the discovery, formulation, development and manufacture of generic drugs. The Company expects its 1st internally-developed ANDA to be filed in 2017, with a total of 2 ANDAs filed by the end of 2017.
GeneriCo is led by a management team with 195 years of combined experience in formulation, manufacturing and commercial leadership. The team has successfully filed and launched over 200 generic drugs and created more than $30B of firm value.
For more information, please visit www.genericopharma.com
GeneriCo Investor Contact: Deborah Knobelman, PhD – Chief Financial Officer Phone Number: +1.646.221.5830 Email: [email protected]
